Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Independent Review Backs Key REFLECT Findings With Lenvatinib in HCC

September 16th 2018

The positive outcomes that lenvatinib demonstrated as first-line therapy for patients with hepatocellular carcinoma are confirmed in an independent assessment conducted as part of the pivotal, international phase III REFLECT trial.

Dr. Cheng on Tumor Heterogeneity in HCC and Challenges for Clinical Trials

September 15th 2018

Ann-Lii Cheng, MD, PhD, distinguished professor and director of the cancer center of National Taiwan University, discusses the challenges that tumor heterogeneity in hepatocellular carcinoma (HCC) pose for clinical trials.

Dr. Abou-Alfa on Key Trends in HCC Research

September 15th 2018

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, describes what he sees as key areas of research into the treatment of hepatocellular carcinoma as therapy moves beyond existing drugs and into novel approaches.

ILCA President Highlights Progress, Looks to the Future of HCC Treatment

September 15th 2018

Morris Sherman, MD, PhD, shared his insight on the news and discussions coming out of this year’s meeting, the surge of immunotherapy and targeted therapy research, optimal sequencing approaches, and the challenges that remain in treating patients with hepatocellular carcinoma.

Second-Line Cabozantinib Proves Effective in HBV+ Liver Cancer

September 15th 2018

Cabozantinib improved survival as second-line therapy for patients with hepatocellular carcinoma who also had a history of hepatitis B virus infection.

Atezolizumab Combo Promising as Frontline HCC Therapy

September 15th 2018

The combination of atezolizumab and bevacizumab demonstrated strong signals of efficacy with a tolerable safety profile as first-line therapy for patients with unresectable or metastatic hepatocellular carcinoma.

Dr. Villanueva on Liquid Biopsy for HCC

September 15th 2018

Augusto Villanueva, MD, PhD, assistant professor, Icahn School of Medicine, discusses the potential of liquid biopsy to improve treatment for patients with hepatocellular carcinoma (HCC).

Dr. Llovet on Biomarkers for HCC

September 15th 2018

Josep M. Llovet, MD, PhD, Icahn School of Medicine, discusses the potential for biomarkers to improve the treatment of hepatocellular carcinoma (HCC).

Novel Agents Prompt Need for New Sequencing Strategies in HCC

September 14th 2018

The rapid development of novel therapies for patients with unresectable hepatocellular carcinoma has dramatically expanded the options for systemic treatments over the past 2 years, creating the need for new sequencing strategies.

Expert Explores Emerging Role of Personalized Medicine in HCC Treatment

September 14th 2018

Updates to the European Association for the Study of the Liver clinical guidelines introduce more opportunities for individual patient management of hepatocellular carcinoma.

Dr. Singal Discusses Recent Clinical Trials in HCC

September 13th 2018

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses recent clinical trials in hepatocellular carcinoma.

Published Results Confirm Regorafenib Safety, Efficacy in mCRC

September 11th 2018

Safety and efficacy findings for regorafenib in patients with previously treated metastatic colorectal cancer were consistent with previous phase III results.

Dr. McCollum on Molecular Testing in CRC

September 10th 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses molecular testing in patients with colorectal cancer (CRC).

Updated Data Confirm Survival, QoL Benefit With Lutathera in GI NETs

September 9th 2018

Jonathan R. Strosberg, MD, discusses the latest NETTER-1 update and the potential impact of Lutathera in patients with gastroenteropancreatic NETs.

Kopetz Highlights Emerging Regimens in Colorectal Cancer

September 7th 2018

Scott Kopetz, MD, PhD, FACP, discusses the current treatment landscape of colorectal cancer and the importance of molecular subtyping.

Expert Discusses Developments in Pancreatic Cancer Paradigm

September 7th 2018

Carlos Becerra, MD, discusses sequencing strategies, immunotherapy, and practice-changing clinical trials in the field of pancreatic cancer.

Dr. Becerra Discusses an Investigational Cellular Therapy in CRC

September 6th 2018

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses an investigational cellular therapy in colorectal cancer.

Dr. Paulson Discusses the Current Treatment for NETs

September 5th 2018

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses the current treatment of patients with neuroendocrine tumors.

Dr. Singal on Emerging Systemic Therapies in HCC

August 31st 2018

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses emerging systemic therapies in hepatocellular carcinoma.

Expert Outlines Clinical Implications of Precision Medicine in GI Cancers

August 31st 2018

Shirley Michelle Shiller, DO, discusses the clinical application of precision medicine in gastrointestinal cancer.